Delving into the Latest Updates on MW-151 with Synapse

HYPOTHESIS: MW151 intervention during whole-brain radiotherapy for intracranial metastases is safe and will mitigate neurocognitive decline.
RATIONALE: There is non-clinical evidence that MW151 reduces brain inflammation and improves neurocognitive outcomes in animal models of radiation therapy induced cognitive dysfunction, and in animal models of other CNS disorders.
PURPOSE: This feasibility trial will study whether MW151 mitigates neurocognitive decline following whole-brain radiotherapy in adult patients with intracranial metastases from solid tumors.

Start Date01 Jul 2022

Sponsor / Collaborator

ImmunoChem Therapeutics, LLC

[+2]

NCT04120233 / CompletedPhase 1IIT

A Phase 1a, Double-Blind, Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of MW151 Administered Orally to Healthy Volunteers

MW01-2-151SRM (=MW151), a small molecule, is being developed for the treatment of cognitive disorders. The development program is based on nonclinical evidence that MW151 improves neurocognitive outcomes in animal models of radiation-induced cognitive impairment, Alzheimer's disease, and other central nervous system (CNS) disorders.
The present study will provide safety and pharmacokinetic (PK) information on single ascending doses to support decisions for continued clinical development.

Start Date22 Oct 2019

Sponsor / Collaborator

University of Kentucky

[+2]

100 Clinical Results associated with MW-151

Login to view more data

100 Translational Medicine associated with MW-151

Login to view more data

100 Patents (Medical) associated with MW-151

Login to view more data

8

Literatures (Medical) associated with MW-151

01 Dec 2015·Journal of NeuroinflammationQ1 · MEDICINE

Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic

Q1 · MEDICINE

ArticleOA

Author: Webster, Scott J ; Morton, Jonathan E ; Van Eldik, Linda J ; Goulding, Danielle S ; Watterson, D Martin ; Bachstetter, Adam D

BACKGROUNDEvidence from clinical studies and preclinical animal models suggests that proinflammatory cytokine overproduction is a potential driving force for pathology progression in traumatic brain injury (TBI). This raises the possibility that selective targeting of the overactive cytokine response, a component of the neuroinflammation that contributes to neuronal dysfunction, may be a useful therapeutic approach. MW151 is a CNS-penetrant, small molecule experimental therapeutic that selectively restores injury- or disease-induced overproduction of proinflammatory cytokines towards homeostasis. We previously reported that MW151 administered post-injury (p.i.) is efficacious in a closed head injury (CHI) model of diffuse TBI in mice. Here we test dose dependence of MW151 to suppress the target mechanism (proinflammatory cytokine up-regulation), and explore the therapeutic window for MW151 efficacy.METHODSWe examined suppression of the acute cytokine surge when MW151 was administered at different times post-injury and the dose-dependence of cytokine suppression. We also tested a more prolonged treatment with MW151 over the first 7 days post-injury and measured the effects on cognitive impairment and glial activation.RESULTSMW151 administered up to 6 h post-injury suppressed the acute cytokine surge, in a dose-dependent manner. Administration of MW151 over the first 7 days post-injury rescues the CHI-induced cognitive impairment and reduces glial activation in the focus area of the CHI.CONCLUSIONSOur results identify a clinically relevant time window post-CHI during which MW151 effectively restores cytokine production back towards normal, with a resultant attenuation of downstream cognitive impairment.

22 Apr 2015·The Journal of NeuroscienceQ1 · MEDICINE

Closed Head Injury in an Age-Related Alzheimer Mouse Model Leads to an Altered Neuroinflammatory Response and Persistent Cognitive Impairment

Q1 · MEDICINE

Article

Author: Van Eldik, Linda J ; Watterson, D Martin ; Bachstetter, Adam D ; Webster, Scott J

Epidemiological studies have associated increased risk of Alzheimer's disease (AD)-related clinical symptoms with a medical history of head injury. Currently, little is known about pathophysiology mechanisms linked to this association. Persistent neuroinflammation is one outcome observed in patients after a single head injury. Neuroinflammation is also present early in relevant brain regions during AD pathology progression. In addition, previous mechanistic studies in animal models link neuroinflammation as a contributor to neuropathology and cognitive impairment in traumatic brain injury (TBI) or AD-related models. Therefore, we explored the potential interplay of neuroinflammatory responses in TBI and AD by analysis of the temporal neuroinflammatory changes after TBI in an AD model, the APP/PS1 knock-in (KI) mouse. Discrete temporal aspects of astrocyte, cytokine, and chemokine responses in the injured KI mice were delayed compared with the injured wild-type mice, with a peak neuroinflammatory response in the injured KI mice occurring at 7 d after injury. The neuroinflammatory responses were more persistent in the injured KI mice, leading to a chronic neuroinflammation. At late time points after injury, KI mice exhibited a significant impairment in radial arm water maze performance compared with sham KI mice or injured wild-type mice. Intervention with a small-molecule experimental therapeutic (MW151) that selectively attenuates proinflammatory cytokine production yielded improved cognitive behavior outcomes, consistent with a link between neuroinflammatory responses and altered risk for AD-associated pathology changes with head injury.

24 Sep 2014·The Journal of NeuroscienceQ1 · MEDICINE

An Anti-Neuroinflammatory That Targets Dysregulated Glia Enhances the Efficacy of CNS-Directed Gene Therapy in Murine Infantile Neuronal Ceroid Lipofuscinosis

Q1 · MEDICINE

Article

Author: Cooper, Jonathan D ; Sands, Mark S ; Pearse, Yewande ; Dearborn, Joshua T ; Watterson, D Martin ; Roberts, Marie S ; Augner, David P ; Macauley, Shannon L ; Fowler, Stephen C ; Shyng, Charles ; Wong, Andrew M S

Infantile neuronal ceroid lipofuscinosis (INCL) is an inherited neurodegenerative lysosomal storage disease (LSD) caused by a deficiency in palmitoyl protein thioesterase-1 (PPT1). Studies inPpt1−/−mice demonstrate that glial activation is central to the pathogenesis of INCL. Astrocyte activation precedes neuronal loss, while cytokine upregulation associated with microglial reactivity occurs before and concurrent with neurodegeneration. Therefore, we hypothesized that cytokine cascades associated with neuroinflammation are important therapeutic targets for the treatment of INCL. MW01–2-151SRM (MW151) is a blood–brain barrier penetrant, small-molecule anti-neuroinflammatory that attenuates glial cytokine upregulation in models of neuroinflammation such as traumatic brain injury, Alzheimer's disease, and kainic acid toxicity. Thus, we used MW151, alone and in combination with CNS-directed, AAV-mediated gene therapy, as a possible treatment for INCL. MW151 alone decreased seizure susceptibility. When combined with AAV-mediated gene therapy, treated INCL mice had increased life spans, improved motor performance, and eradication of seizures. Combination-treated INCL mice also had decreased brain atrophy, astrocytosis, and microglial activation, as well as intermediary effects on cytokine upregulation. These data suggest that MW151 can attenuate seizure susceptibility but is most effective when used in conjunction with a therapy that targets the primary genetic defect.

100 Deals associated with MW-151

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Poisoning	Phase 1	-	University of Kentucky	-
Brain Injuries, Traumatic	Preclinical	US	-	31 Oct 2019
Drug intoxication	Preclinical	US	National Institute on Aging	22 Oct 2019
Cognition Disorders	Preclinical	US	-	29 Sep 2019
Alzheimer Disease	Preclinical	US	-	21 Sep 2019
Multiple Sclerosis	Preclinical	US	-	20 Sep 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04120233 (CTgov)	Phase 1	Drug intoxication	40	Placebo (Placebo)	kjiggvphkw(vhaccjfwip) = coqtddyehj chkugmeene (jcdmzgsmmh, tdjidqmgtq - rijqkzzqzk) View more	-	30 Dec 2022
				MW151, 10mg (Dose 1)	kjiggvphkw(vhaccjfwip) = eertfasxgl chkugmeene (jcdmzgsmmh, wgunzcwrmm - vuqwhwenbs) View more